Population Difference in the Associations of KLOTH Promoter Methylation with Mild Cognitive Impairment in Xinjiang Uygur and Han Populations

Mei Luo1‡, Xiaohui Zhou1*, Huihui Ji2‡, Wenjuan Ma1, Guili Liu2, Dongjun Dai2, Jingyun Li2, Lan Chang2, Lei Xu2, Litong Jiang2, Shiwei Duan2*, Qinwen Wang2*

1 Department of Internal Medicine for Cadres, the First Affiliated Hospital of Xinjiang Medical University, Urumchi, 830000, China, 2 Ningbo Key Lab of Behavior Neuroscience, Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo, Zhejiang, 315211, China

‡ These authors are co-first authors of this work.
* zhouxiaohui858@sina.com (XZ); duanshiwei@nbu.edu.cn (SD); wangqinwen@nbu.edu.cn (QW)

Abstract

Background
Mild cognitive impairment (MCI) is the intermediate stage of the cognitive changes between normal aging and dementia. KLOTH is an age-related gene that may contribute to the risk of MCI. The aim of our study was to explore the association between KLOTHO promoter methylation and MCI in Xinjiang Uygur and Han populations.

Methods
DNA methylation assay was performed using the bisulphite pyrosequencing technology among 96 Uygur (48 MCI and 48 controls) and 96 Han (48 MCI and 48 controls) Chinese individuals from Xinjiang province of China.

Results
We found significant association between KLOTHO promoter methylation and MCI in the Han Chinese (CpG1: p = 3.77E-06; CpG2: p = 1.91E-07; CpG3: p = 5.83E-07; CpG4: p = 2.23E-05; CpG5: p = 3.03E-06) but not in the Uygur Chinese. Higher KLOTHO promoter methylation levels were found in Han MCI patients than Uygur MCI patients for all the five CpGs (adjusted p values by age < 0.02).

Conclusion
Our results showed that KLOTHO promoter hypermethylation contributed to the MCI risk in Xinjiang Han Chinese but not in Xinjiang Uygur Chinese. The population difference of KLOTHO methylation in the risk of MCI required further investigation in the future.
Introduction

Mild cognitive impairment (MCI) refers to the intermediate stage of the cognitive changes between normal aging and dementia [1]. Individuals with MCI showed cognitive impairment greater than expected for their age and education, but their mental functions are relative complete and do not reach the criteria for dementia. About 10–15% of MCI persons develop into dementia (mostly Alzheimer’s disease, AD) per year, in constrast of 1–2% AD incidence in the general population per year [2]. The incidence of MCI ranges from 1% to 6% per year, while the prevalence ranges from 3% to 22% per year [3, 4] in the Western countries. In China, the prevalences of MCI in different regions vary between 5.4% (Taiyuan city) and 25% (Shaanxi province) [5]. Nowadays, MCI has become a major threat to the eldly, and it should be early detected and intervened in order to delay or prevent the occurrence of dementia.

*KLOTHO* is a longevity and neuroprotective gene [6], encoding a single-pass transmembrane protein with a long extracellular domain and a short cytoplasmic tail [7]. *KLOTHO* controls multiple growth factor signaling pathways, including insulin, IGF-1 and Wnt [8]. Klotho is able to protect cells and tissues from oxidative stress by stimulating the expression of antioxidant proteins [9]. Klotho-mutated mice had cognition impairment due to an increased oxidative damage to hippocampus neurons [10], and the similar result was also observed in rhesus monkey [11, 12]. Lower KLOTHO concentration was discovered in the cerebrospinal fluid of older adults, especially in the AD patients [13]. Our previous study indicated lower KLOTHO protein levels in MCI patients than controls [14].

Alteration in promoter methylation is often found to affect gene expression [15] and was shown to be associated with AD [16], and other diseases [17–20]. MCI is a complex disease affected by both genetic and environmental factors [21]. Epigenetics is considered as a link between genetics and environment, and DNA methylation as a major part of epigenetics may play an important role in the development of MCI [22]. Aberrant expression of some important genes, such as APOE [23], presenilin 1 and APP [24], were shown to be associated with the occurrence of MCI. However, the relationship between *KLOTHO* methylation and MCI is still unclear. Therefore, we examined whether *KLOTHO* promoter methylation was associated with MCI in the Han and Uygur Chinese in Xinjiang province of China.

Materials and Methods

Samples and clinical data

All the participants over 60 were selected in this study. Among them, there were 96 MCI patients (48 Han and 48 Uygur) and 96 well-matched controls (48 Han and 48 Uygur) collected from epidemiological surveys between 2010 and 2014 in Xinjiang province of China. According to the Diagnostic and Statistical Manual of Mental Disorders 4th edition, the inclusion criteria for MCI comprised the following items: 1) memory complaint; 2) GDS scores were 2–3 grade and MMSE scores for illiterate, primary school and secondary school (and above) were 18–21, 21–24, and 25–27, respectively; 3) decreased daily activities and social participation; 4) HIS score ≤ 4 and no specific causes of cognitive decline; 5) cognitive impairment lasted for over three months; 6) absence of dementia. Subjects were excluded if they had history of mental illness or mental retardation or suffering from severe heart or lung or kidney dysfunction, severe endocrine disease, severe infectious diseases, and toxic encephalopathy. Subjects were also excluded if they had brain dysfunctions in the past 6 months, including stroke, Parkinson’s disease, brain tumors, depression, a history of head trauma, or a history of psychoactive drug use, alcohol, or drug addiction. All the collected individuals were Han or Uygur Chinese from Xinjiang in the Western China. All the subjects voluntarily participated in this
study. Written informed consent was obtained from each of the subjects following a complete description of the study. The institutional ethics committee of the First Affiliated Hospital at Xinjiang Medical University approved this study.

Biochemical analyses

Nucleic acid was extracted from the blood samples using the Genomic DNA Mini Kit (TIANGEN; Beijing, China). The DNA concentration was measured by the ultramicro nucleic acid ultraviolet tester (NANODROP 1000, Wilmington, USA). Plasma levels of biochemical factors (including triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL)) were detected by biochemical laboratory (Beckman; Brea, CA, USA). DNA methylation levels of each CpG sites were tested by pyrosequencing technology. Sodium bisulfite (EZ DNA Methylation-Gold Kit; ZYMO RESEARCH, Orange County, California, USA) was used to convert all unmethylated cytosines to uracils, and meanwhile the methylated cytosines unchanged. Polymerase chain reaction (PCR) (Zymo Taq PreMix, ZYMO RESEARCH, Orange County, California, USA) was used to augment target DNA sequences. The primers were all designed by PyroMark Assay Design software. The sequences were 5′-TTGGGTTTTT GAGTGGGAGAAAAGT-3′ (forward primer), 5′-Biotin-AAACCCTCAAATTCATTCTCTT TACCTACC-3′ (reverse primer), and was 5′-AGTGAGAGTAGGTGT-3′ (sequencing primer). All the oligomers were synthesized by the Sangon Biotechnology company (Shanghai, China).

Statistical Program for Social Sciences (SPSS) software 16.0 (SPSS, Inc., Chicago, IL, USA) was used in this study and a \( p \) value < 0.05 was considered to be significant. Nonparametric testing was used to compare differences in the each CpG sites of continuous variables between the MCI cases and controls. Spearman rank correlation test was used to analyze the associations between KLOTH methylation and metabolic characteristics of MCI subjects.

Results

A total of five CpGs on the KLOTHO promoter were assessed to explore their associations with the risk of MCI (Fig 1). Significant correlation was found among the methylation levels of the five CpGs (\( r > 0.524, p < 0.001 \)). As shown in Table 1 and Fig 2, significantly elevated KLOTHO promoter methylation was found in MCI cases than controls in Xinjiang Han
Chinese population (CpG1: \( p = 3.77 \times 10^{-6} \); CpG2: \( p = 1.91 \times 10^{-7} \); CpG3: \( p = 5.83 \times 10^{-7} \); CpG4: \( p = 2.23 \times 10^{-5} \); CpG5: \( p = 3.03 \times 10^{-6} \)) but not in Uygur Chinese population. Similar results in the female and male Xinjiang Han Chinese (male: CpG1: \( p = 0.001 \); CpG2: \( p = 2.36 \times 10^{-4} \); CpG3: \( p = 0.003 \); CpG4: \( p = 0.007 \); CpG5: \( p = 0.002 \), female: CpG1: \( p = 0.001 \); CpG2: \( p = 3.23 \times 10^{-4} \); CpG3: \( p = 1.89 \times 10^{-5} \); CpG4: \( p = 0.001 \); CpG5: \( p = 4.18 \times 10^{-4} \), Table 2).

Since there were significant differences in the age between Uygur and Han samples (MCI cases: \( p = 6.78 \times 10^{-9} \); controls: \( p = 3.22 \times 10^{-9} \), Table 3), thus the population differences of various parameters were adjusted by age. According to the Table 3 and Fig 3, Han MCI patients had significantly higher levels of \( KLOTHO \) promoter DNA methylation than Uygur MCI patients (CpG1: adjusted \( p = 4.27 \times 10^{-4} \); CpG2: adjusted \( p = 0.017 \); CpG3: adjusted \( p = 0.002 \); CpG4: adjusted \( p = 0.005 \); CpG5: adjusted \( p = 0.001 \)).

Among the 5 phenotypes, significantly higher TC and lower HDL-C levels were found in the Uygur MCI patients than the Uygur controls (TC: \( p = 0.030 \); HDL-C: \( p = 0.010 \), Fig 4). Lower levels of HDL-C were found in the Uygur MCI females than the Uygur female controls.

---

Table 1. Characteristics of \( KLOTHO \) methylation and important parameters in the Xinjiang Uygur and Han Chinese.

|               | Uygur          | Han            | p value | Table 1. Characteristics of \( KLOTHO \) methylation and important parameters in the Xinjiang Uygur and Han Chinese. | Han            | p value |
|---------------|----------------|----------------|---------|---------------------------------------------------------------|----------------|---------|
| BMI           | 23.59±3.76     | 23.12±4.14     | 0.57    | 24.49±2.78                                                   | 24.49±3.33     | 0.986   |
| Age(years)    | 70.83±4.54     | 71.02±4.42     | 0.838   | 77.41±5.52                                                   | 77.70±5.53     | 0.797   |
| CpG1          | 6(6,7)         | 6(6,7)         | 0.565   | 10(7,11.75)                                                  | 6(6,7)         | 3.77E-06|
| CpG2          | 2(2,3)         | 2(2,2)         | 0.342   | 3(3.25,4)                                                   | 2(2,2)         | 5.83E-07|
| CpG3          | 2(1,2)         | 2(1,2)         | 0.907   | 3(2,4)                                                      | 2(2,2)         | 5.83E-07|
| CpG4          | 5(5,5)         | 5(5,6)         | 0.900   | 8(5,8)                                                      | 5(5,5)         | 2.23E-05|
| CpG5          | 4(3,4)         | 3(3,4)         | 0.566   | 6(4,8)                                                      | 4(3,5)         | 3.03E-06|

doi:10.1371/journal.pone.0132156.t001

---

Fig 2. Association between \( KLOTHO \) methylation and MCI.

doi:10.1371/journal.pone.0132156.g002
(p = 0.024, Fig 4). In the Xinjiang Han Chinese, significantly higher levels of TC and LDL-C were found in the male MCI patients compared to the male controls (TC: p = 0.045, LDL-C: p = 0.005, Fig 4).

After adjusted by age, significantly higher levels of TC, LDL-C, and HDL-C were found in Han MCI patients than Uygur MCI patients (TC: adjusted p = 0.042; LDL-C: adjusted p = 0.011; HDL-C: adjusted p = 0.011, Fig 4). Significantly lower TG and higher TC and LDL-C levels were found in Han controls than Uygur controls (TG: adjusted p = 0.043; TC: adjusted p = 4.63E-04; LDL-C: adjusted p = 0.008, Fig 4). Besides, significantly higher levels of LDL-C were found in Han patients than Uygur patients (adjusted p = 0.049, Fig 4).

As shown in the Table 4, statistically higher levels of CpG sites were found in Han MCI patients than Uygur MCI patients in the male and female subgroups (male: CpG1: adjusted p = 0.009; CpG2: adjusted p = 0.047; CpG3: adjusted p = 0.009; CpG5: adjusted p = 0.034, Table 4; female: CpG1: adjusted p = 0.012; CpG4: adjusted p = 0.017; CpG5: adjusted p = 0.006, Table 4). In the male subgroup, the levels of TC and LDL-C were all significantly higher in Han patients compared to Uygur patients (TC: adjusted p = 0.023; LDL-C: adjusted p = 0.005, Fig 4).

Table 2. Subgroup characteristics of KLOTHO methylation and important parameters in the Xinjiang Uygur and Han Chinese.

|          | Uygur          | Han            |
|----------|----------------|----------------|
|          | Case(n = 24)   | Control(n = 24) |
|          | p value        | p value        |
| male     |                |                |
| BMI      | 24.96±4.32     | 23.72±3.53     | 0.283 |
|          | 25.34±2.82     | 24.15±2.37     | 0.121 |
| Age(years)| 72.00±5.00    | 72.46±4.46     | 0.739 |
|          | 78.33±6.32     | 78.71±6.27     | 0.837 |
| CpG1     | 6(6,7)         | 7(6,7)         | 0.469 |
|          | 10(7,11.75)    | 6(6,7)         | 0.001 |
| CpG2     | 2(2,2)         | 2(2,2)         | 0.928 |
|          | 3(3,4)         | 2(2,2)         | 2.36E-04 |
| CpG3     | 2(2,2)         | 2(2,2)         | 0.217 |
|          | 3(3,4)         | 2(2,3)         | 0.003 |
| CpG4     | 5(5,5)         | 5(5,6)         | 0.484 |
|          | 7.5(5,8)       | 5(4,5)         | 0.007 |
| CpG5     | 3(3,4)         | 3(3,4)         | 0.572 |
|          | 6(4,7)         | 4(3,5)         | 0.002 |

| female   |                |                |
| BMI      | 22.21±2.53     | 22.53±4.69     | 0.774 |
|          | 23.64±2.52     | 24.85±4.11     | 0.226 |
| Age(years)| 69.67±3.81     | 69.58±3.98     | 0.941 |
|          | 76.50±4.55     | 76.71±4.60     | 0.875 |
| CpG1     | 6.5(6,7)       | 6(6,7)         | 0.125 |
|          | 9.5(6,11.75)   | 6(5.25,7)      | 0.001 |
| CpG2     | 2(2,3)         | 2(2,2)         | 0.228 |
|          | 3(2,4)         | 2(2,2)         | 3.23E-04 |
| CpG3     | 2(2,2)         | 2(1,2)         | 0.123 |
|          | 3(2,4)         | 2(2,2)         | 1.89E-05 |
| CpG4     | 5(5,5)         | 5(4,5)         | 0.518 |
|          | 8(5,8)         | 5(5,5)         | 0.001 |
| CpG5     | 4(3,4)         | 3(3,4)         | 0.149 |
|          | 7(4,8)         | 4(3,4)         | 4.184E-04 |

doi:10.1371/journal.pone.0132156.t002

Table 3. Tests for population differences of KLOTHO methylation and important parameters.

|          | Han            | Uygur          | p value | adjusted p value (by age) | Han            | Uygur          | p value | adjusted p value (by age) |
|----------|----------------|----------------|---------|--------------------------|----------------|----------------|---------|--------------------------|
| BMI      | 24.49±2.78     | 23.58±3.76     | 0.186   |                          | 24.49±3.34     | 23.12±4.14     | 0.077   |                          |
| Age(years)| 77.42±5.52    | 70.83±4.54     | 6.78E-09|                          | 77.71±5.53     | 71.02±4.42     | 3.22E-09|                          |
| CpG1     | 10(7,11.75)    | 6(6,7)         | 1.39E-05| 4.27E-04                  | 6(6,7)         | 6(6,7)         | 0.973   | 0.870                     |
| CpG2     | 3(2,25,4)      | 2(2,3)         | 1.03E-04| 0.017                     | 2(2,2)         | 2(2,2)         | 0.288   | 0.195                     |
| CpG3     | 3(2,4)         | 2(1,2)         | 1.11E-06| 0.002                     | 2(2,2)         | 2(1,2)         | 0.126   | 0.347                     |
| CpG4     | 8(5,8)         | 5(5,5)         | 7.97E-05| 0.005                     | 5(5,5)         | 5(5,6)         | 0.333   | 0.542                     |
| CpG5     | 6(4,8)         | 4(3,4)         | 9.04E-07| 0.001                     | 4(3,5)         | 3(3,4)         | 0.668   | 0.865                     |

doi:10.1371/journal.pone.0132156.t003
Association of KLOTHO Promoter Methylation with MCI in Xinjiang

Fig 3. Population difference of KLOTHO methylation.

doi:10.1371/journal.pone.0132156.g003

Fig 4. Differences of important parameters between Xinjiang Uygur and Han populations.

doi:10.1371/journal.pone.0132156.g004

Significantly higher TC levels were also found in the male Han controls compared to the male Uygur controls (adjusted p = 0.049, Fig 4). In the females, significantly higher levels of HDL-C were found in the Han MCI patients than the Uygur MCI patients (adjusted
p = 0.023, Fig 4). Statistically higher levels of TC and LDL-C were found in Han female MCI compared to Uygur female controls (TC: adjusted p = 0.011; LDL-C: adjusted p = 0.015, Fig 4).

**Discussion**

In the current study, we investigated the association between *KLOTHO* promoter methylation and MCI in two Xinjiang populations. In the Xinjiang Han, significant results were found in the overall analysis and the gender-based subgroup analyses, although no positive results existed in the Uygur population. Significantly higher level of *KLOTHO* promoter methylation was found in Han patients compared to Uygur patients. In addition, population differences were also found in multiple clinical phenotypes including the levels of TG, TC, HDL-C and LDL-C. Different dietary cultures in two populations might explain the population differences of the above phenotypes.

*KLOTHO* is a longevity gene and has been considered to be involved in MCI which is an age-related disease. *KLOTHO* mainly expressed in brain and kidney, secreting into CSF and serum, respectively [25]. *KLOTHO* as a related factor to oxidative damage has the ability to protect neurons in brain [26]. *KLOTHO* was considered as an aging suppressor gene [27], and over expression of *KLOTHO* significantly extended the life span of mice [28, 29]. Meanwhile, we found a higher methylation level in *KLOTHO* promoter in the MCI patients of Xinjiang Han population than matched controls, and the same results were also observed in the subgroup stratified by gender. No difference was found in Uygur population. DNA methylation alteration of promoter was often found to influence gene expression [30]. In addition, hypermethylation of *KLOTHO* was shown to low expression in hepatocellular carcinoma tissues [31]. Repressions of *KLOTHO* might have an adverse effect for MCI patients according to a previous study [27]. Hence, we hypothesized that hypermethylation of *KLOTHO* promoter might play a role in the development of MCI of Xinjiang Han population via the pathway of down regulation of *KLOTHO* expression.
Population difference could change gene activity as described previously [32]. Populations are complicated in Xinjiang Province. Uygur population and Han population belong to Caucasian and Mongolian, respectively [33]. Previous study had investigated significant association between IL-4, IFN-gamma promoter methylation and allergic rhinitis patients of Uygur and Han Chinese in Xinjiang [34]. Significantly higher DNA methylation levels of microRNA-375 promoter were found in Han T2D patients than Kazak T2D patients in Xinjiang [35]. In this study, significantly higher level of KLOTHO promoter methylation was discovered in Han MCI patients than Uygur patients, suggesting a population specific mode of KLOTHO methylation in the susceptibility of MCI.

Dyslipidemia is associated with both the occurrence and progression of MCI. HDL-C and TC were belong to vascular risk factors and could increase the risk of MCI and the risk of conversion from MCI to AD [36, 37]. A correlation between HDL-C and dementia was also revealed in the elderly [38]. A cross-sectional study about cognitive impairment suggested that TC and LDL-C were independent risk factors for MCI [39]. An interdisciplinary longitudinal study showed that higher TC levels were associated with an increased risk for cognitive disorders [40]. Higher TC and lower HDL-C levels were found in Chinese T2D patients with MCI compared to simple T2D patients [41]. Consistent with the previous findings, our study showed a significantly higher TC level in MCI compared to controls in the Uygur population.

Population differences were also found in four phenotypes including TG, TC, HDL-C and LDL-C. Higher levels of TC and LDL-C were found in Han population than Uygur population in both MCI and control subgroup. However, elevation of HDL-C level was only found in the Han MCI patients than Uygur MCI patients. In addition, significantly lower levels of TG were found in Han patients and controls than Uygur patients and controls. These phenotypes are shown to be influenced by many factors including genetic factors, eating habit, and lifestyle [42, 43]. The population differences in both the genetic and the environmental factors might explain the differences of above phenotypes in two populations.

Ethnic difference has been observed in the diagnosis, clinical manifestation, disease management, prevalence, and cause of MCI. Race difference was found in the memory performance even after adjusting by the status of education, depression, gender, and memory complaints [44]. As the measurement of cognitive functioning, Hachinski ischemic scale scores were shown to differ by ethnicity [45]. African American MCI patients were found to have faster rate of cognitive decline compared with non-African American ones [46]. Ethnic disparities were also observed in the management of MCI patients [47]. Caucasian MCI patients underwent significant more neuropsychologic testing; while African-Americans had more depression screening tests and were less likely to be prescribed with acetylcholinesterase inhibitors [47]. The prevalence of dementia has been reported to be higher among African Americans and Caribbean Hispanics, lower among Japanese Americans, and similar among Native Americans and Mexican Americans compared with non-Hispanic whites [48]. English usage in Australia was shown to be related to lower prevalence of MCI and higher rates of reversion from MCI to normal [49]. In the United States, more African American and Hispanic MCI patients were attributable to diabetes than non-Hispanic white MCI patients [50]. Racial disparities in financial capacity were found to exist among patients with amnestic MCI [51]. Predictive risk factors for MCI in non-Hispanic cohorts were not associated with MCI in Mexican Americans [52], who were more likely to be possessed the ApoE ε4 allele less frequently [52]. In addition, ApoE ε4 allele was protective for MCI only in Han Chinese but not in Hui Chinese [53].

In summary, our study identified the contribution of KLOTHO promoter methylation to MCI in Xinjiang Han population. The lack of significant results in the Xinjiang Uygur population might be due to the differences in genetics and environment. Further investigation on the population difference was needed in the future.
Acknowledgments
The research was supported by the grants from the National Natural Science Foundation of China (81471398, 81070873, 31100919 and 81371469), 973 program from the Ministry of Science and Technology of China (2013CB835100), Natural Science Foundation of Zhejiang Province (LR13H020003), Disciplinary Project of Ningbo University (B01350104900), and K. C. Wong Magna Fund in Ningbo University.

Author Contributions
Conceived and designed the experiments: SD QW XZ. Performed the experiments: ML HJ WM GL LX LJ. Analyzed the data: ML HJ. Contributed reagents/materials/analysis tools: DD JL LC. Wrote the paper: ML HJ.

References
1. Christa Maree Stephan B, Minett T, Pagett E, Siervo M, Brayne C, McKeith IG. Diagnosing Mild Cognitive Impairment (MCI) in clinical trials: a systematic review. BMJ open. 2013; 3(2). Epub 2013/02/07. doi: 10.1136/bmjopen-2012-001909 PMID: 23386579; PubMed Central PMCID: PMC3586181.
2. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Archives of neurology. 2001; 58(12):1985–92. Epub 2001/12/26. PMID:11735772.
3. Larrieu S, Letenneur L, Orgogozo JM, Fabrigoule C, Amieva H, Le Carret N, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002; 59 (10):1594–9. Epub 2002/11/27. PMID: 12451203.
4. Hanninen T, Hallikainen M, Tuomainen S, Vanhanen M, Soininen H. Prevalence of mild cognitive impairment: a population-based study in elderly subjects. Acta neurologica Scandinavica. 2002; 106 (3):148–54. Epub 2002/08/14. PMID: 12174174.
5. Cheng Y, Xiao S. Recent research about mild cognitive impairment in China. Shanghai archives of psychiatry. 2014; 26(1):4–14. Epub 2014/08/13. doi: 10.3969/j.issn.1002-0829.2014.01.002 PMID: 25111476; PubMed Central PMCID: PMC4117997.
6. Zeldich E, Chen CD, Colvin TA, Bove-Fenderson EA, Liang J, Tucker Zhou TB, et al. The neuroprotective effect of Klotho is mediated via regulation of members of the redox system. The Journal of biological chemistry. 2014; 289(35):24700–15. Epub 2014/07/20. doi: 10.1074/jbc.M114.567321 PMID: 25037225; PubMed Central PMCID: PMC4148892.
7. Hahn D, Lottaz D, Sterchi EE. C-cytosolic and transmembrane domains of the N-benzoyl-L-tyrosyl-p-aminobenzoic acid hydrolase alpha subunit (human meprin alpha) are essential for its retention in the endoplasmic reticulum and C-terminal processing. European journal of biochemistry / FEBS. 1997; 247 (3):933–41. Epub 1997/08/01. PMID: 9288917.
8. Alvarez A, Cacabelos R, Sanpedro C, Garcia-Fantini M, Alexandre M. Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiology of aging. 2007; 28(4):533–6. Epub 2006/03/30. doi: 10.1016/j.neurobiolaging.2006.02.012 PMID: 16569464.
9. Takahashi G, Sakurai M, Abe K, Itoyama Y, Tabayashi K. MCI-186 reduces oxidative cellular damage and increases DNA repair function in the rabbit spinal cord after transient ischemia. The Annals of thoracic surgery. 2004; 78(2):602–7. Epub 2004/07/28. doi: 10.1016/j.athoracsur.2004.02.133 PMID: 15276530.
10. Nagai T, Yamada K, Kim HC, Kim YS, Noda Y, Imura A, et al. Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2003; 17(1):50–2. Epub 2002/12/12. doi: 10.1096/fj.02-0448fje PMID: 12475907.
11. Cherubini A, Spoletini I, Peran P, Luccichenti G, Di Paola M, Sancesario G, et al. A multimodal MRI investigation of the subventricular zone in mild cognitive impairment and Alzheimer's disease patients. Neuroscience letters. 2010; 469(2):214–8. Epub 2009/12/08. doi: 10.1016/j.neulet.2009.11.077 PMID: 19962428.
12. Dohnel K, Sommer M, Ibach B, Rothmayr C, Meinhardt J, Hajak G. Neural correlates of emotional working memory in patients with mild cognitive impairment. Neuropsychologia. 2008; 46(1):37–48. Epub 2007/10/05. doi: 10.1016/j.neuropsychologia.2007.08.012 PMID: 17915264.
13. Sembá RD, Moghekar AR, Hu J, Sun K, Turner R, Ferrucci L, et al. Klotho in the cerebrospinal fluid of adults with and without Alzheimer's disease. Neuroscience letters. 2014; 558:37–40. Epub 2013/11/12. doi: 10.1016/j.neulet.2013.10.058 PMID: 24211699; PubMed Central PMCID: PMC4037850.
14. Xiaohui Zhou ZY, Haijun Miao. Relationship of serum Klotho protein content with mild cognitive impairment. Chin J Psychiatry. 2014; 47(1):4. Epub February.

15. Yu Z, Kong Q, Kone BC. Aldosterone reprograms promoter methylation to regulate alphaENaC transcription in the collecting duct. American journal of physiology Renal physiology. 2013; 305(7):F1006–13. Epub 2013/08/09. doi: 10.1152/ajprenal.00407.2013 PMID: 23926181; PubMed Central PMCID: PMC3798741.

16. Chang L, Wang Y, Ji H, Dai D, Xu X, Jiang D, et al. Elevation of peripheral BDNF promoter methylation links to the risk of Alzheimer's disease. PloS one. 2014; 9(11):e110773. Epub 2014/11/05. doi: 10.1371/journal.pone.0110773 PMID: 25364831; PubMed Central PMCID: PMC4217733.

17. Dai D, Cheng J, Zhou K, Lv Y, Zhuang Q, Zheng R, et al. Significant association between DRD3 gene body methylation and schizophrenia. Psychiatry research. 2014; 220(3):772–7. Epub 2014/09/30. doi: 10.1016/j.psychres.2014.08.032 PMID: 25282640.

18. Xu L, Zheng D, Wang L, Jiang D, Liu H, Liao Q, et al. GCK gene-body hypomethylation is associated with the risk of coronary heart disease. BioMed research international. 2014; 2014:151723. Epub 2014/04/04. doi: 10.1155/2014/151723 PMID: 24696842; PubMed Central PMCID: PMC3947703.

19. Zhang LN, Liu PP, Wang L, Yuan F, Xu L, Xin Y, et al. Lower ADD1 gene promoter DNA methylation increases the risk of essential hypertension. PloS one. 2013; 8(5):e63455. Epub 2013/05/22. doi: 10.1371/journal.pone.0063455 PMID: 23691048; PubMed Central PMCID: PMC3655193.

20. Jiang D, Zheng D, Wang L, Huang Y, Liu H, Xu L, et al. Elevated PL2AG7 gene promoter methylation as a gender-specific marker of aging increases the risk of coronary heart disease in females. PloS one. 2013; 8(3):e59752. Epub 2013/04/05. doi: 10.1371/journal.pone.0059752 PMID: 23555769; PubMed Central PMCID: PMC3610900.

21. Young JW, Sharkey J, Finlayson K. Progressive impairment in olfactory working memory in a mouse model of Mild Cognitive Impairment. Neurobiology of aging. 2009; 30(9):1430–43. Epub 2008/02/05. doi: 10.1016/j.neurobiolaging.2007.11.018 PMID: 18242780.

22. Coppe F, Migliore L. Evidence linking genetics, environment, and epigenetics to impaired DNA repair in Alzheimer's disease. Journal of Alzheimer's disease: JAD. 2010; 20(4):953–66. Epub 2010/02/26. doi: 10.3233/JAD-2010-1415 PMID: 20182042.

23. Caselli RJ. Phenotypic differences between apolipoprotein E genetic subgroups: research and clinical implications. Alzheimer's research & therapy. 2012; 4(3):20. Epub 2012/06/15. doi: 10.1186/alzrt123 PMID: 22694803; PubMed Central PMCID: PMC3506934.

24. Lin HC, Hsieh HM, Chen YH, Hu ML. S-Adenosylhomocysteine increases beta-amyloid formation in BV-2 microglial cells by increased expressions of beta-amyloid precursor protein and presenilin 1 and by hypomethylation of these gene promoters. Neurotoxicology. 2009; 30(4):622–7. Epub 2009/07/29. doi: 10.1016/j.neuro.2009.03.011 PMID: 19635394.

25. Chen CD, Tung TY, Liang J, Zeldich E, Tucker Zhou TB, Turk BE, et al. Identification of cleavage sites leading to the shed form of the anti-aging protein klotho. Biochemistry. 2014; 53(34):5579–87. Epub 2014/08/12. doi: 10.1021/bi500409n PMID: 25110992; PubMed Central PMCID: PMC4151695.

26. Brobey R. GD, Gurnani P., Pastor J., Hsieh C.-C., Papaconstantinou J., Kuro-o M., Rosenblatt K. P., editor Klotho activation is neuroprotective against oxidative stress through antioxidant and apoptotic signaling pathways2011; Houston, TX.

27. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, et al. Suppression of aging in mice by the hormone Klotho. Science. 2005; 309(5742):1829–33. Epub 2005/08/27. doi: 10.1126/science.1112766 PMID: 18123266; PubMed Central PMCID: PMC2536606.

28. Kuro-o M. Klotho as a regulator of oxidative stress and senescence. Biological chemistry. 2006; 387(3):233–41. Epub 2008/01/08. doi: 10.1515/BC.2008.028 PMID: 18177265.

29. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsumi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390(6655):45–51. Epub 1997/11/18. doi: 10.1038/36285 PMID: 9363890.

30. Razin A, Cedar H. DNA methylation and gene expression. Microbiological reviews. 1991; 55(3):451–8. Epub 1991/09/01. PMID: 1943996; PubMed Central PMCID: PMC3728289.

31. Xie B, Zhou J, Yuan L, Ren F, Liu DC, Li Q, et al. Epigenetic silencing of Klotho expression correlates with poor prognosis of human hepatocellular carcinoma. Human pathology. 2013; 44(5):795–801. Epub 2012/11/06. doi: 10.1016/j.humpath.2012.07.023 PMID: 23123137.

32. Zhang JP, Zhou SF, Chen X, Huang M. Determination of intra-ethnic differences in the polymorphisms of thiopurine S-methyltransferase in Chinese. Clinica chimica acta; international journal of clinical chemistry. 2006; 365(1–2):337–41. Epub 2005/10/15. doi: 10.1016/j.cca.2005.09.005 PMID: 16223474.
33. Shan M, Wang X, Sun G, Ma B, Yao X, Ainy A, et al. A retrospective study of the clinical differences of Uyghur breast cancer patients compared to Han breast cancer patients in the Xinjiang region of China. International journal of clinical and experimental medicine. 2014; 7(10):3482–90. Epub 2014/11/25. PMID: 25419387; PubMed Central PMCID: PMC4238510.

34. Lou Z, Wang H, Yang Q, Jiang X, Zhang Q, Mu NR, et al. [Comparative study of IL-4, IFN-gamma gene methylation for the epigenetics of allergic rhinitis in Xinjiang Uyghur, Han people]. Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery. 2012; 26 (18):795–7. Epub 2012/12/25. PMID: 23259293.

35. Chang X, Li S, Li J, Yin L, Zhou T, Zhang C, et al. Ethnic differences in microRNA-375 expression level and DNA methylation status in type 2 diabetes of Han and Kazak populations. Journal of diabetes research. 2014; 2014:761938. Epub 2014/04/18. doi: 10.1155/2014/761938; PubMed Central PMCID: PMC3972833.

36. Blasko I, Kemmler G, Jungwirth S, Wichart I, Weissgram S, Jellinger K, et al. Prospective study on association between plasma amyloid beta-42 and atherosclerotic risk factors. J Neural Transm. 2011; 118(5):663–72. Epub 2011/02/24. doi: 10.1007/s00038-011-0599-4 PMID: 21344293.

37. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 2005; 65(4):545–51. Epub 2005/08/24. doi: 10.1212/01.wnl.0000172914.08967.de PMID: 16116114; PubMed Central PMCID: PMC1619359.

38. Porowski T, Kaluza B. [Metabolic syndrome and cognitive dysfunction in the old age]. Psychiatria polska. 2013; 47(6):1087–99. Epub 2014/07/11. PMID: 25007540.

39. Zou Y, Zhu Q, Deng Y, Duan J, Pan L, Tu Q, et al. Vascular risk factors and mild cognitive impairment in the elderly population in Southwest China. American journal of Alzheimer’s disease and other dementias. 2014; 29(3):242–7. Epub 2014/01/01. doi: 10.1177/1533317513517042 PMID: 24375574.

40. Toro P, Degen C, Pierer M, Gustafson D, Schroeder J, Schonknecht P. Cholesterol in mild cognitive impairment and Alzheimer’s disease in a birth cohort over 14 years. European archives of psychiatry and clinical neuroscience. 2014; 264(6):485–92. Epub 2013/11/19. doi: 10.1007/s00406-013-0468-2 PMID: 24241689.

41. Niu MJ, Yin FZ, Liu LX, Fang Y, Xuan XM, Wu GF. Non-high-density lipoprotein cholesterol and other risk factors of mild cognitive impairment among Chinese type 2 diabetic patients. Journal of diabetes and its complications. 2013; 27(5):443–6. Epub 2013/07/13. doi: 10.1016/j.jdiacomp.2013.06.001 PMID: 23845902.

42. Gupta R, Misra A, Vikram NK, Kondal D, Gupta SS, Agrawal A, et al. Younger age of escalation of cardiovascular risk factors in Asian Indian subjects. BMC cardiovascular disorders. 2009; 9:28. Epub 2009/07/07. doi: 10.1186/1471-2261-9-28 PMID: 19575817; PubMed Central PMCID: PMC2713196.

43. Merkin SS, Karlamangla A, Crimmins E, Charette SL, Hayward M, Kim JK, et al. Education differentials in vascular risk factors among community-dwelling elders with mild cognitive impairment be accurately diagnosed in english speakers from linguistic minorities? Results from the Sydney Memory and Ageing study. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry. 2012; 20(10):866–77. Epub 2012/01/21. doi: 10.1097/JGP.0b013e31823e31e2 PMID: 22261551.
50. Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Archives of neurology. 2007; 64(4):570–5. Epub 2007/04/11. doi: 10.1001/archneur.64.4.570 PMID: 17420320.

51. Triebel KL, Okonkwo OC, Martin R, Griffith HR, Crowther M, Marson DC. Financial capacity of older African Americans with amnestic mild cognitive impairment. Alzheimer disease and associated disorders. 2010; 24(4):365–71. Epub 2010/07/14. doi: 10.1097/WAD.0b013e3181e7cb05 PMID: 20625268; PubMed Central PMCID: PMC2992589.

52. O’Bryant SE, Johnson L, Baldin V, Edwards M, Barber R, Williams B, et al. Characterization of Mexican Americans with mild cognitive impairment and Alzheimer’s disease. Journal of Alzheimer’s disease: JAD. 2013; 33(2):373–9. Epub 2012/09/15. doi: 10.3233/JAD-2012-121420 PMID: 22976076; PubMed Central PMCID: PMC3524411.

53. Wang Z, Ma W, Rong Y, Liu L. The Association between Apolipoprotein E Gene Polymorphism and Mild Cognitive Impairment among Different Ethnic Minority Groups in China. International journal of Alzheimer’s disease. 2014; 2014:150628. Epub 2014/08/28. doi: 10.1155/2014/150628 PMID: 25161798; PubMed Central PMCID: PMC4138891.